AU2003282171A8 - Method for diagnosing rhabdomyosarcoma and pharmaceutical compositions for the treatment and/or prevention of rhabdomyosarcoma - Google Patents

Method for diagnosing rhabdomyosarcoma and pharmaceutical compositions for the treatment and/or prevention of rhabdomyosarcoma

Info

Publication number
AU2003282171A8
AU2003282171A8 AU2003282171A AU2003282171A AU2003282171A8 AU 2003282171 A8 AU2003282171 A8 AU 2003282171A8 AU 2003282171 A AU2003282171 A AU 2003282171A AU 2003282171 A AU2003282171 A AU 2003282171A AU 2003282171 A8 AU2003282171 A8 AU 2003282171A8
Authority
AU
Australia
Prior art keywords
rhabdomyosarcoma
diagnosing
prevention
treatment
pharmaceutical compositions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2003282171A
Other versions
AU2003282171A1 (en
Inventor
Cecile Gauthier-Rouviere
Franck Comunale
Sophie Charrasse Poulat
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Centre National de la Recherche Scientifique CNRS
Original Assignee
Centre National de la Recherche Scientifique CNRS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FR0211525A external-priority patent/FR2844597B1/en
Application filed by Centre National de la Recherche Scientifique CNRS filed Critical Centre National de la Recherche Scientifique CNRS
Publication of AU2003282171A8 publication Critical patent/AU2003282171A8/en
Publication of AU2003282171A1 publication Critical patent/AU2003282171A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Hospice & Palliative Care (AREA)
  • Food Science & Technology (AREA)
  • Oncology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
AU2003282171A 2002-09-17 2003-09-17 Method for diagnosing rhabdomyosarcoma and pharmaceutical compositions for the treatment and/or prevention of rhabdomyosarcoma Abandoned AU2003282171A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
FR0211525A FR2844597B1 (en) 2002-09-17 2002-09-17 METHOD FOR THE DIAGNOSIS OF EMBRYONIC RHABDOMYOSARCOMA AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT AND / OR PREVENTION OF EMBRYONIC RHABDOMYOSARCOMA
FR02/11525 2002-09-17
FR03/08623 2003-07-15
FR0308623A FR2844598B1 (en) 2002-09-17 2003-07-15 METHOD FOR THE DIAGNOSIS OF RHABDOMYOSARCOMA AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT AND / OR PREVENTION OF RHABDOMYOSARCOMA
PCT/FR2003/002741 WO2004027372A2 (en) 2002-09-17 2003-09-17 Method for diagnosing rhabdomyosarcoma and pharmaceutical compositions for the treatment and/or prevention of rhabdomyosarcoma

Publications (2)

Publication Number Publication Date
AU2003282171A8 true AU2003282171A8 (en) 2004-04-08
AU2003282171A1 AU2003282171A1 (en) 2004-04-08

Family

ID=31947979

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003282171A Abandoned AU2003282171A1 (en) 2002-09-17 2003-09-17 Method for diagnosing rhabdomyosarcoma and pharmaceutical compositions for the treatment and/or prevention of rhabdomyosarcoma

Country Status (3)

Country Link
AU (1) AU2003282171A1 (en)
FR (1) FR2844598B1 (en)
WO (1) WO2004027372A2 (en)

Also Published As

Publication number Publication date
WO2004027372A3 (en) 2004-06-10
FR2844598B1 (en) 2006-05-19
FR2844598A1 (en) 2004-03-19
WO2004027372A2 (en) 2004-04-01
AU2003282171A1 (en) 2004-04-08

Similar Documents

Publication Publication Date Title
HK1152474A1 (en) Methods and compositions for the prevention and treatment of sepsis
EP1416961A4 (en) Composition and method for the treatment of disease
IL158181A0 (en) N-acetylcysteine compositions and methods for the treatment and prevention of drug toxicity
IL165950A0 (en) Compositions and method for the diagnosis and treatment of tumor
EP1571968A4 (en) Compositions and methods for the diagnosis and treatment of tumor
EP1589933A4 (en) Compositions and methods for the diagnosis and treatment of tumor
EP1575480A4 (en) Compositions and methods for the treatment of immune related diseases
EP1578367A4 (en) Compositions and methods for the treatment of immune related diseases
EP1572116A4 (en) Compositions and methods for the treatment of immune related diseases
EP1576137A4 (en) Compositions and methods for the treatment of immune related diseases
HUS1300073I1 (en) Fluoro substituted omega-carboxyaryl diphenyl urea for the treatment and prevention of diseases and conditions
AU2003290548A8 (en) Prevention and treatment of synucleinopathic disease
HRP20040906B1 (en) Bisphosphonic acid for the treatment and prevention of ostreoporosis
EP1711197A4 (en) Methods and compositions for the prevention and treatment of inflammatory diseases or conditions
EP1553912A4 (en) Compositions and methods for the diagnosis and treatment of tumor
EP1578996A4 (en) Compositions and methods for the diagnosis and treatment of tumor
AU2003290605A8 (en) Compositions and methods for the diagnosis and treatment of sepsis
EP1575571A4 (en) Compositions and methods for the diagnosis and treatment of tumor
AU2003291480A8 (en) Composition for the prevention and treatment of inflammation of the ear
HK1082923A1 (en) Synergistic compositions for the prevention and treatment of acquired immunodeficiency
AU2003291536A8 (en) Method for the diagnosis and treatment of vascular disease
AU2003244132A8 (en) Method of examining allergic disaese and drug for treating the same
IL166062A0 (en) Compositions and methods for therapeutic treatment
AU2003282171A8 (en) Method for diagnosing rhabdomyosarcoma and pharmaceutical compositions for the treatment and/or prevention of rhabdomyosarcoma
EP1572130A4 (en) Compositions and methods for the treatment of immune related diseases

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase